Liquidia Corp (LQDA)
10.01
-0.13
(-1.28%)
USD |
NASDAQ |
Sep 27, 16:00
10.01
0.00 (0.00%)
After-Hours: 20:00
Liquidia SG&A Expense (TTM): 67.90M for June 30, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 67.90M |
March 31, 2024 | 57.20M |
December 31, 2023 | 44.74M |
September 30, 2023 | 33.78M |
June 30, 2023 | 29.97M |
March 31, 2023 | 27.66M |
December 31, 2022 | 32.41M |
September 30, 2022 | 34.69M |
June 30, 2022 | 32.83M |
March 31, 2022 | 30.32M |
December 31, 2021 | 23.11M |
September 30, 2021 | 25.81M |
June 30, 2021 | 28.08M |
March 31, 2021 | 28.88M |
Date | Value |
---|---|
December 31, 2020 | 27.37M |
September 30, 2020 | 21.99M |
June 30, 2020 | 17.22M |
March 31, 2020 | 14.40M |
December 31, 2019 | 13.60M |
September 30, 2019 | 10.14M |
June 30, 2019 | 10.04M |
March 31, 2019 | 9.626M |
December 31, 2018 | 8.754M |
September 30, 2018 | 8.558M |
June 30, 2018 | 9.279M |
March 31, 2018 | 10.21M |
December 31, 2017 | 10.21M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
10.14M
Minimum
Sep 2019
67.90M
Maximum
Jun 2024
30.10M
Average
28.48M
Median
SG&A Expense (TTM) Benchmarks
United Therapeutics Corp | 581.80M |
Arcturus Therapeutics Holdings Inc | 53.05M |
Paragon 28 Inc | 196.60M |
Tonix Pharmaceuticals Holding Corp | 37.14M |
AIM ImmunoTech Inc | 22.70M |